Drug Approval | August 19, 2022
Tavneos recommended by England’s NICE for the treatment of AAV
The decision follows authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in May 2022.
The decision follows authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in May 2022.
DEP® ADCs exploit the unique potential of Starpharma's DEP® technology to provide enhanced characteristics to ADCs i
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Naproxen Sodium Capsules, 220 mg, of Bionpharma
Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines
The OAI classification implies that the US FDA may withhold approval of any pending product applications or supplements filed from this facility till the outstanding observations are resolved
Collaboration supports multiple discovery efforts, including vaccines
The card-to-cloud device was launched into the U.S. and many other markets and is designed to work without an embedded communications module.
The estimated capex is to the tune of Rs. 140 crore to be funded through debt and internal accrual
The approved product has an estimated market size of around US$ 606 million for the twelve months ending June 2022, according to IQVIA.
ELCYS is the only FDA-approved cysteine hydrochloride injection on the market for use as an additive to amino acid solutions
Subscribe To Our Newsletter & Stay Updated
